

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCA United States Patent and Trudemark Office

And the second second

APPLICATION NO	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO	CONFIRMATION NO
09.699,295	10/26/2000	Tony N. Frudakis	210121 4190 10	64×4
500 = =	590 10 17 2002			
SEED INTELLECTUAL PROPERTY LAW GROUP PLLC 701 FIFTH AVE SUITE 6300 SEATTLE, WA 98104-7092			EXAMINER	
			ZEMAN, MARY K	
			ARTUNII	PAPER NUMBER
			(63)	١
			DATE MAILED: 10/17/2002	12
				/

Please find below and or attached an Office communication concerning this application or proceeding.

Applicant(s) Application No. FRUDAKIS ET AL 09/699.295 Office Action Summary Examiner Art Unit Mary K Zeman 1631 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133) Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). **Status** 1)[Responsive to communication(s) filed on 07 August 2002. 2a)[·] 2b) This action is non-final. This action is FINAL. Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. **Disposition of Claims** 4) Claim(s) 3,4 and 18-20 is/are pending in the application. 4a) Of the above claim(s) _____ is/are withdrawn from consideration. 5) Claim(s) 3,4,18 and 19 is/are allowed. 6) Claim(s) 20 is/are rejected. 7) Claim(s) _____ is/are objected to. 8) Claim(s) _____ are subject to restriction and/or election requirement. **Application Papers** 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action. 12) The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. §§ 119 and 120 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. ___ 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s) 1) Notice of References Cited (PTO-892) Interview Summary (PTO-413) Paper No(s). 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Notice of Informal Patent Application (PTO-152) Information Disclosure Statement(s) (PTO-1449) Paper No(s) ___ Other

DETAILED ACTION

This application contains claims 2, 5-7, 9, 10, 12-14, 16 and 17 drawn to an invention nonelected without traverse in Paper No. 7. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Applicant's arguments filed 8/7/02 have been fully considered but they are not completely persuasive.

Rejection maintained

Claim 20 remains rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a written description rejection.

The specification discloses SEQ ID NO: 301 which corresponds to a reconstructed sequence encoding a polypeptide of SEQ ID NO: 304. Claim 20 is directed to encompass, sequences that hybridize to SEQ ID NO: 301 under moderately stringent conditions. Other than the specifically disclosed sequences, none of these sequences meet the written description provision of 35 USC 112, first paragraph. The specification provides insufficient written description to support the genus encompassed by the claim.

Applicant argues that the disclosure of the genomic sequence and a few variants of the sequence provides written basis for the enormous genus of sequences encompassed by clam 20. This is not persuasive, as the genus is so large, and ill defined, that one of skill in the art would not be apprised of what Applicant considers to fall within its scope. The definition of a polynucleotide by a function (hybridization under moderately stringent conditions) fails to provide enough specific detail as to what is being claimed.

<u>Vas-Cath Inc. v. Mahurkar</u>, 19 USPQ2d 1111, makes clear that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession *of the invention*. The invention is, for purposes of the 'written description' inquiry, whatever is now claimed." (See page 1117.) The specification does not "clearly allow persons

Art Unit: 1631

of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See <u>Vas-Cath</u> at page 1116.)

With the exception of SEQ ID NO: 301 and the related disclosed sequences, the skilled artisan cannot envision the detailed chemical structure of the encompassed polynucleotides and/or proteins, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it. The nucleic acid itself is required. See <u>Fiers v. Revel</u>, 25 USPQ2d 1601, 1606 (CAFC 1993) and <u>Amgen Inc. V. Chugai Pharmaceutical Co. Ltd.</u>, 18 USPQ2d 1016. In <u>Fiddes v. Baird</u>, 30 USPQ2d 1481, 1483, claims directed to mammalian FGF's were found unpatentable due to lack of written description for the broad class. The specification provided only the bovine sequence.

The species specifically disclosed in this application are not representative of the genus because the genus is highly variant. Applicant is reminded that <u>Vas-Cath</u> makes clear that the written description provision of 35 USC 112 is severable from its enablement provision. (See page 1115.)

New Grounds of Rejection Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 20 is rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new grounds of rejection necessitated by Applicant's amendment. This is a new matter rejection.

The new limitation in claim 20 of "wherein said oligonucleotide hybridizes to at least a portion of the nucleotide sequence of SEQ ID NO: 301 from nucleotide 1 to nucleotide 61" is new matter. This portion (or any portion) of SEQ ID NO: 301 is at no point noted for its

Art Unit: 1631

particular interest, or usefulness in diagnostic capabilities. Applicant has not provided basis for such a limitation in the specification, and none is apparent.

Conclusion

Claims 3, 4, 18 and 19 are allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mary K Zeman whose telephone number is (703) 305-7133.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward, can be reached at (703) 308-4028.

Official fax numbers for this Art Unit are: (703) 308-4242, (703) 872-9306. An *unofficial* fax number, direct to the Examiner is (703) 746 5279. Please call prior to use of this number.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the TC1600 Receptionist whose telephone number is (703) 308-0196.

mkz 10/16/02

> MARY K. ZEMAN PRIMARY EXAMINER

10 631